What Researchers Did
Researchers reviewed the latest treatments and strategies for managing mucormycosis, a serious and often life-threatening fungal infection.
What They Found
The review found that lipid formulations of amphotericin B (LFAB) are the main treatment for mucormycosis. Posaconazole may be used as a backup treatment, but not as the first choice. Combination therapies, such as LFAB with echinocandin or deferasirox, showed potential in early studies and animal models, while polyene-posaconazole combinations were not beneficial. Hyperbaric oxygen therapy was also mentioned as an adjunctive treatment for selected patients.
What This Means for Canadian Patients
For Canadian patients with mucormycosis, this review highlights the importance of early diagnosis and treatment with established therapies like LFAB. It also suggests that adjunctive treatments, including hyperbaric oxygen therapy (HBOT), could be considered for certain patients to improve outcomes. Patients should discuss these options with their healthcare providers to determine the best course of action.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The review notes that many promising treatments, including combination therapies, require further definitive and randomized clinical trials to confirm their effectiveness in humans.